BMO Capital Markets Initiates Coverage on Avidity Biosciences (NASDAQ:RNA)
BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $72.00 price target on the biotechnology company’s stock. RNA has been the topic of several other reports. Chardan Capital reiterated a […]
BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $72.00 price target on the biotechnology company’s stock. RNA has been the topic of several other reports. Chardan Capital reiterated a […]
